Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIM CTL
- Development stage
- Unknown
- Lead developer
- NexImmune
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
AIM CTL (Artificial Immune Modulation-primed Cytotoxic T Lymphocytes) is an adoptive cell therapy developed by NexImmune using its proprietary AIM platform. The platform utilizes nanoparticles that mimic dendritic cell function by presenting MHC-peptide complexes (Signal 1) and anti-CD28 costimulatory molecules (Signal 2) to selectively activate and expand endogenous, multi-antigen-specific CD8+ T cells from a patient's blood. These expanded CTLs are characterized by a rejuvenated phenotype and high specificity for tumor-associated antigens (TAAs). AIM CTLs are being investigated for the treatment of hematologic malignancies, including multiple myeloma and acute myeloid leukemia, both as a monotherapy and in combination with T-cell engagers (TCEs) to enhance anti-tumor efficacy and persistence.
- Other names
- AIM-primed CTLArtificial Immune Modulation-primed Cytotoxic T Lymphocytes
02
Targets
CD28 (Cluster of Differentiation 28)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on AIM CTL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIM CTL.